Isolated Atrioventricular Block in the Fetus: A Retrospective, Multinational, Multicenter Study of 175 Patients

Background— Isolated complete atrioventricular block in the fetus is a rare but potentially lethal condition in which the effect of steroid treatment on outcome is unclear. The objective of this work was to study risk factors associated with death and the influence of steroid treatment on outcome. Methods and Results— We studied 175 fetuses diagnosed with second- or third-degree atrioventricular block (2000–2007) retrospectively in a multinational, multicenter setting. In 80% of 162 pregnancies with documented antibody status, atrioventricular block was associated with maternal anti-Ro/SSA antibodies. Sixty-seven cases (38%) were treated with fluorinated corticosteroids for a median of 10 weeks (1–21 weeks). Ninety-one percent were alive at birth, and survival in the neonatal period was 93%, similar in steroid-treated and untreated fetuses, regardless of degree of block and/or presence of anti-Ro/SSA. Variables associated with death were gestational age <20 weeks, ventricular rate ⩽50 bpm, fetal hydrops, and impaired left ventricular function at diagnosis. The presence of ≥1 of these variables was associated with a 10-fold increase in mortality before birth and a 6-fold increase in the neonatal period independently of treatment. Except for a lower gestational age at diagnosis in treated than untreated (23.4±2.9 versus 24.9±4.9 weeks; P=0.02), risk factors were distributed equally between treatment groups. Two-thirds of survivors had a pacemaker by 1 year of age; 8 children developed cardiomyopathy. Conclusions— Risk factors associated with a poor outcome were gestation <20 weeks, ventricular rate ⩽50 bpm, hydrops, and impaired left ventricular function. No significant effect of treatment with fluorinated corticosteroids was seen.

[1]  D. Friedman,et al.  Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the research registry for neonatal lupus. , 1999, Arthritis and rheumatism.

[2]  J. Smallhorn,et al.  Transplacental Fetal Treatment Improves the Outcome of Prenatally Diagnosed Complete Atrioventricular Block Without Structural Heart Disease , 2004, Circulation.

[3]  C. Doré,et al.  The Effects of Repeated Antenatal Glucocorticoid Therapy on the Developing Brain , 2001, Pediatric Research.

[4]  V. Aiello,et al.  Perinatal Outcome of Fetal Atrioventricular Block: One-Hundred-Sixteen Cases From a Single Institution , 2008, Circulation.

[5]  A. Tincani,et al.  Electrocardiographic abnormalities in infants born from mothers with autoimmune diseases--a multicentre prospective study. , 2007, Rheumatology.

[6]  J. Piette,et al.  Questions about dexamethasone use for the prevention of anti-SSA related congenital heart block , 2003, Annals of the rheumatic diseases.

[7]  J. Buyon,et al.  Spectrum and progression of conduction abnormalities in infants born to mothers with anti-SSA/Ro-SSB/La antibodies , 2002, Lupus.

[8]  M. A. Engle,et al.  Congenital complete heart block: an international study of the natural history. , 1972, Cardiovascular clinics.

[9]  A. Baschat,et al.  Atrioventricular block detected in fetal life: associated anomalies and potential prognostic markers , 2005, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[10]  E. Theander,et al.  Primary Sjögren's syndrome--treatment of fetal incomplete atrioventricular block with dexamethasone. , 2001, The Journal of rheumatology.

[11]  P. Stoutenbeek,et al.  Treatment of fetal heart block with maternal steroid therapy: case report and review of the literature , 2004, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[12]  E. Rosenthal,et al.  Therapeutic trial of sympathomimetics in three cases of complete heart block in the fetus. , 1995, Circulation.

[13]  Robert M Hamilton,et al.  Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block. A single institution's experience of 30 years. , 2002, Journal of the American College of Cardiology.

[14]  E. Rosenthal,et al.  Letter regarding article by Jaeggi et al, "transplacental fetal treatment improves the outcome of prenatally diagnosed complete atrioventricular block without structural heart disease". , 2005, Circulation.

[15]  J. Fouron,et al.  Fetal Doppler echocardiographic diagnosis and successful steroid therapy of Luciani-Wenckebach phenomenon and endocardial fibroelastosis related to maternal anti-Ro and anti-La antibodies. , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[16]  J. Buyon,et al.  Successful in utero therapy of fetal heart block. , 1995, American journal of obstetrics and gynecology.

[17]  F. Hsieh,et al.  Etiology and outcome of hydrops fetalis. , 1998, Journal of the Formosan Medical Association = Taiwan yi zhi.

[18]  A. Whitelaw,et al.  Antenatal steroids and the developing brain , 2000, Archives of disease in childhood. Fetal and neonatal edition.

[19]  É. Marijon,et al.  Presentation and prognosis of complete atrioventricular block in childhood, according to maternal antibody status. , 2006, Journal of the American College of Cardiology.

[20]  R. Wakai,et al.  Atrial and ventricular rate response and patterns of heart rate acceleration during maternal-fetal terbutaline treatment of fetal complete heart block. , 2007, The American journal of cardiology.